Venaxis Files for Public Offering, Targets $18.4M in Net Proceeds | GenomeWeb

NEW YORK (GenomeWeb News) – Venaxis today priced the public offering of about 8.3 million shares of its common stock at $2.40 per share.

Net proceeds from the offering are expected at around $18.4 million, which the Castle Rock, Colo.-based firm will use for working capital and other corporate purposes, including the sales and marketing of its APPY1 appendicitis test in the European Union, and development efforts to expand and improve the test's performance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."